Oncology-focused pharma: branded oncology/derma drugs, CDMO manufacturing, APIs, and IVF products via Nivian.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| Reserves | 48 | 59 | 83 | 113 | 148 | 187 | 211 | 235 |
| Borrowings | 23 | 17 | 21 | 20 | 15 | 138 | 146 | 148 |
| Other Liabilities | 28 | 31 | 45 | 55 | 82 | 101 | 121 | 103 |
| Total Liabilities | 107 | 118 | 158 | 198 | 254 | 436 | 488 | 496 |
| AssetsFixed Assets | 44 | 40 | 55 | 63 | 65 | 89 | 112 | 125 |
| CWIP | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 63 | 74 | 102 | 135 | 190 | 347 | 376 | 371 |
| Total Assets | 107 | 118 | 158 | 198 | 254 | 436 | 488 | 496 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | 0 | 8 | 19 | 30 | 23 | 31 | 36 | 37 |
| Cash from Investing | -21 | -15 | -6 | -22 | -19 | -14 | -36 | -51 |
| Cash from Financing | 12 | 9 | -8 | -1 | -2 | -7 | 118 | -8 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -21 | -7 | 13 | 10 | 5 | 19 | -1 | -16 |
| FCF Margin | — | — | — | — | — | — | — | — |
An earnings-based reverse DCF needs positive, normalized profits. This business doesn't have them yet, so any 'fair value' would be fiction.
BETA · LOSS_MAKING
Guides on how to read this kind of business and the numbers that matter.